Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

A New Dawn in the Management of Idiopathic Hypersomnia: An Adaptive Learning Approach to Diagnosis and Implementing Clinical Trial Updates

Adaptive Learning

Premiere Date: Wednesday, January 18, 2023

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, January 18, 2024
Note: Credit Is No Longer Available

Faculty

Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS  Professor of Neurology Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Director, Cleveland Clinic Sleep Disorders Center Cleveland, OH

Statement of Need

Idiopathic hypersomnia (IH) is a chronic, debilitating sleep disorder mainly characterized by excessive daytime sleepiness (EDS) as well as prolonged nocturnal sleep and/or daytime naps, unrefreshing sleep, sleep inertia, and autonomic dysfunction. These symptoms, in turn, often result in diminished psychosocial functioning, cognitive dysfunction, school/work performance, and quality of life (QoL), subsequently impacting family, friends, and work colleagues, as well as public health and safety. Contributing to the debilitation caused by IH is the failure of health care practitioners (HCPs) to accurately diagnose IH in a timely manner. In fact, an accurate diagnosis can often take years, leaving patients with IH struggling with personal, work, and psychosocial dysfunction in the interim.

While advances in sleep medicine have resulted in the first and only FDA-approved therapy for IH, incorporating this therapy into practice and monitoring treatment efficacy requires best practices. Please join Dr. Foldvary-Schaefer in this adaptive learning activity for a personalized journey through the latest clinical evidence for IH, strategies to transition patients to new therapies, and evidence-based tools to assess symptom severity and treatment effectiveness.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recognize the burden of IH.
• Utilize validated tools to measure the impact of IH on function and QoL.
• Assess the efficacy and safety data for novel agents to manage IH.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care providers, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format:

Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Foldvary-Schaefer reports the following financial relationships:

Advisory Board: Jazz Pharmaceuticals, Inc. (Publication Committee)

Research Support: Jazz Pharmaceuticals, Inc.; Suven Pharmaceuticals Limited; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals

The following Peer Reviewer and CME Outfitters staff reports no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Kashemi D. Rorie, PhD (planning committee)

Evan Luberger (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sandra Caballero, PharmD (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).